A5073756618- Esophageal Cancer Research and Treatment
- Gastric Cancer Management and Outcomes
- Helicobacter pylori-related gastroenterology studies
- Esophageal and GI Pathology
- Cancer Cells and Metastasis
- Eosinophilic Esophagitis
- Metastasis and carcinoma case studies
- Occupational and environmental lung diseases
- Pancreatic and Hepatic Oncology Research
- Gastroesophageal reflux and treatments
- Epigenetics and DNA Methylation
- Drug Transport and Resistance Mechanisms
- Cancer-related gene regulation
- IL-33, ST2, and ILC Pathways
- RNA modifications and cancer
- Liver Disease Diagnosis and Treatment
- Digestive system and related health
- Heat shock proteins research
- Immune cells in cancer
- Genetic factors in colorectal cancer
- Diet, Metabolism, and Disease
University Medical Center Freiburg
2021-2025
Technical University of Munich
2018-2024
Klinikum rechts der Isar
2017-2022
Near-infrared (NIR) fluorescence imaging has been emerging as a promising strategy to overcome the high number of early esophageal adenocarcinomas missed by white light endoscopy and random biopsy collection. We performed preclinical assessment using novel CXCR4-targeted fluorescent peptide ligand in L2-IL1B mouse model Barrett's esophagus. Six mice with advanced stage disease (12-16 months old) were injected CXCR4-targeted, Sulfo-Cy5-labeled (MK007), ex vivo wide-field whole stomach was 4 h...
Abstract Barrett’s esophagus (BE) is a precursor to esophageal adenocarcinoma (EAC), but its cellular origin and mechanism of neoplastic progression remain unresolved. Notch signaling, which plays key role in regulating intestinal stem cell maintenance, has been implicated number cancers. The kinase Dclk1 labels epithelial post-mitotic tuft cells at the squamo-columnar junction (SCJ), also proposed contribute tumor growth. Here, we find that genetic activation intracellular signaling...
Abstract Purpose The incidence of esophageal adenocarcinoma (EAC) has been increasing for decades without significant improvements in treatment. Barrett’s esophagus (BE) is best established risk factor EAC, but current surveillance with random biopsies cannot predict progression to cancer most BE patients due the low sensitivity and specificity high-definition white light endoscopy. Methods Here, we evaluated membrane-bound highly specific Hsp70-specific contrast agent Tumor-Penetrating...
Abstract Chronic inflammation induces Barrett’s Esophagus (BE) which can advance to esophageal adenocarcinoma. Elevated levels of interleukin (IL)-1b, IL-6 and IL-8 together with activated nuclear factor-kappaB (NF-κB), have been identified as important mediators tumorigenesis. The inflammatory milieu apart from cancer cells infiltrating immune contains myofibroblasts (MFs) that express aSMA Vimentin. As we observed increased NF-κB activation correlates MF recruitment an accelerated...
Esophageal adenocarcinoma (EAC) is mostly prevalent in industrialized countries and has been associated with obesity, commonly linked a diet rich fat refined sugars containing high fructose concentrations. In meta-organisms, dietary components are digested metabolized by the host its gut microbiota. Fructose shown to induce proliferation cell growth pancreas colon cancer lines also alter previous study L2-IL-1B mouse model, we showed that high-fat (HFD) accelerated EAC progression from...
The incidence of Barrett esophagus (BE) and Gastroesophageal Adenocarcinoma (GEAC) correlates with obesity a diet rich in fat. Bile acids (BA) support fat digestion undergo microbial metabolization the gut. farnesoid X receptor (FXR) is an important modulator BA homeostasis. capacity inhibiting cancer-related processes when activated, make FXR appealing therapeutic target. In this work, we assess role on microbiota-BA axis evaluate disease progression.
SUMMARY Risk stratification in patients with Barrett's esophagus (BE) to prevent the development of esophageal adenocarcinoma (EAC) is an unsolved task. The incidence EAC and BE increasing are still at unknown risk. BarrettNET ongoing multicenter prospective cohort study initiated identify validate molecular clinical biomarkers that allow a more personalized surveillance strategy for BE. For participants recruited 20 centers throughout Germany, be followed progression dysplasia (low-grade or...
// Vincenz Sahm 1 , Carlo Maurer Theresa Baumeister 3 Akanksha Anand Julia Strangmann Roland M. Schmid Timothy C. Wang 2 and Michael Quante II Medizinische Klinik, Technische Universität München, Munich, Germany Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA Klinik für Innere Medizin II, Universitätsklinikum Freiburg, Correspondence to: Quante, email: michael.quante@uniklinik-freiburg.de Keywords: Barrett's esophagus; telomere shortening; esophageal...
Barrett's esophagus (BE) is the main known precursor condition of esophageal adenocarcinoma (EAC). BE defined by presence metaplasia above normal squamous columnar junction and has mainly been attributed to gastroesophageal reflux disease chronic esophagitis. Thus, rising incidence EAC in Western world probably mediated inflammation, secondary combination with environmental risk factors such as a diet obesity. However, (at present) prediction tools endoscopic surveillance have shown limited...
Abstract Objective The incidence of gastro-esophageal adenocarcinoma (GEAC) has increased dramatically and is associated with Barrett’s Esophagus (BE). Gastric cardia progenitors are the likely origin for BE GEAC. Here we analyze p53, Rb1 Kras alterations in Lgr5 progenitor cells during carcinogenesis. Design We introduced single combined genetic ( ) Lgr5-expressing at inflamed gastroesophageal junction L2-IL1b (L2) mouse model crossed to Lgr5-Cre ERT mice. For in-vitro treatment utilized...